厄洛替尼对EGFR外显子19与21突变晚期非小细胞肺癌患者的疗效比较  

Efficacy Comparison of Erlotinib between Late Non-small Cell Lung Cancer Patients with EGFR Exon 19 Mutation and Those with Exon 21 Mutation

作　　者：翁克贵[1] 郭兵[2] 候彦华 蒋勇[1] 王颖[1] 王渝东[2] 

机构地区：[1]重庆市肿瘤研究所/重庆市肿瘤医院/重庆市癌症中心肿瘤放疗科,重庆400030 [2]重庆医药高等专科学校生理教研室,重庆401331

出　　处：《中国药房》2018年第1期81-84,共4页China Pharmacy

摘　　要：目的:比较厄洛替尼对表皮生长因子受体(EGFR)外显子19与21突变晚期非小细胞肺癌(NSCLC)患者的临床疗效。方法:选取我院2013年10月-2014年11月收治的EGFR突变阳性的晚期NSCLC患者,将EGFR外显子19 Del突变者分为A组,外显子21 L858R突变者分为B组,每组45例。两组患者均口服盐酸厄洛替尼片至进展。比较两组患者疾病控制率(DCR)、中位生存时间(MST)、中位进展时间(m TTP)、一年生存率以及不良反应发生率。结果:A组患者的DCR(93.02%)、一年生存率(81.40%)均明显高于B组(72.09%、60.47%)(P<0.05),MST[(15.47±2.87)个月]与m TTP[(182.00±8.24)d]均明显长于B组[(12.55±2.92)个月、(162.00±7.22)d](P<0.01),两组患者的不良反应发生率比较差异无统计学意义(P>0.05),且均未见严重不良反应发生。结论:对于晚期NSCLC患者,厄洛替尼对EGFR外显子19突变患者的疗效优于EGFR外显子21突变患者。OBJECTIVE： To compare the clinical efficacy of erlotinib between late non-small cell lung cancer （NSCLC） pa- tients with epidermal growth factor receptor （EGFR） exon 19 mutation and those with exon 21 mutation. METHODS： Late NSCLC patients with EGFR mutation positive enrolled in our hospital during Oct. 2013-Nov. 2014 were selected. Patients with EG- FR exon 19 Del mutant were regarded as group A, and patients with exon 21 L858R mutant were regarded as group B, 45 cases in each group. All patients were orally administered with Erlotinib hydrochloride tablets till progression. The disease control rate （DCR）, median survival time （MST）, median time to progress （mTTP）, one-year survival rate and incidence of adverse reactions in 2 groups were compared. RESULTS： The DCR （93.02%） and one-year survival rate （81.40%） in group A were obviously higher than that of group B （72.09%, 60.47%） （P〈0.05）, MST [（15.47 ± 2.87） month] and mTTP [（182.00 ± 8.24） d] were obviously longer than that of group B [（ 12.55 ± 2.92） month, （162.00 ± 7.22） d] （P〈0.01）. There was no statistical significance in the incidence of adverse reactions in 2 groups （P〉0.05）, and there were no severe adverse reactions. CONCLUSIONS： For patients with late NSCLC, erlotinib shows superior efficacy in patients with EGFR exon 19 mutation to patients with EGFR exon 21 muta- tion.

关 键 词：酪氨酸激酶抑制剂 厄洛替尼 表皮生长因子受体 晚期非小细胞肺癌 疗效 

分 类 号：R734.2[医药卫生—肿瘤]